Krajnak, Slavomir http://orcid.org/0000-0002-8012-5772
Jäkel, Jörg
Anić, Katharina
Schwab, Roxana
Schmidt, Marcus
Hasenburg, Annette
Roth, Wilfried
Brenner, Walburgis
Battista, Marco Johannes
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 24 July 2021
Accepted: 11 October 2021
First Online: 24 October 2021
Declarations
:
: SK received speaker honoraria from Roche Pharma AG; research funding from Novartis and travel reimbursement from PharmaMar. MS received personal fees from AstraZeneca, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work; institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre-Fabre, and Roche; and travel reimbursement from Pfizer and Roche. AH received personal fees from AstraZeneca, Celgen, GSK, LEO Pharma, MedConcept GmbH, Med update GmbH, Medicultus, PharmaMar, Pfizer, Promedicis GmbH, Softconsult, Roche Pharma AG, Streamedup! GmbH, Tesaro Bio Germany GmbH. MJB received honoraria and travel reimbursement from Roche Pharma AG, Tesaro Bio GmbH, Glaxo Smith Kline, Clovis Oncology, Astra Zeneca, Pharma Mar GmbH, Celgene, Pierre-Fabre Pharma GmbH. All remaining authors have no conflicts of interest.
: The study was approved by the Research Ethics Committee of the University Medical Center Mainz, Germany. Informed consent was obtained from all the patients, and all the clinical investigations were conducted according to the ethical and legal standards, and with the 1964 Helsinki Declaration and its later amendments.
: Informed consent to participate in the study was obtained from all participants.
: All participants consented to the publication of the study.